Advertisement

Management of Prostate Cancer: EAU Guidelines on Screening, Diagnosis and Treatment

  • Axel Heidenreich
Chapter

Abstract

The current chapter summarizes the most recent version of the EAU guidelines on screening, diagnosis and treatment of cancer of the prostate (CaP). A literature review of the new data emerging from 2007 to 2010 has been performed by the working panel. The guidelines have been updated and level of evidence/grade of recommendation added to the text based on a systematic review of the literature, which included a search of online databases and bibliographic reviews. A full version is available at the EAU Office or at www.uroweb.org.

The knowledge in the field of prostate cancer is rapidly changing. These EAU guidelines on prostate cancer summarize the most recent findings and put them into clinical practice.

Keywords

Gleason Score Abiraterone Acetate Maximum Androgen Blockade Intermittent Androgen Deprivation Salvage Radical Prostatectomy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Abrahamsson PA (2010) Potential benefits of intermittent androgen suppression therapy in the treatment of ­prostate cancer: a systematic review of the literature. Eur Urol 57(1):49–59PubMedCrossRefGoogle Scholar
  2. Adamakis I, Mitropoulos D, Haritopoulos K, Alamanis C, Stravodimos K, Giannopoulos A (2004) Pain during transrectal ultrasonography guided prostate biopsy: a randomized prospective trial comparing periprostatic infiltration with lidocaine with the intrarectal instillation of lidocaine- prilocain cream. World J Urol 22(4):281–284PubMedCrossRefGoogle Scholar
  3. Al Otaibi M, Ross P, Fahmy N, Jeyaganth S, Trottier H, Sircar K, Bégin LR, Souhami L, Kassouf W, Aprikian A, Tanguay S (2008) Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance. Cancer 113(2):286–292PubMedCrossRefGoogle Scholar
  4. Albertsen PC, Hanley JA, Gleason DF, Barry MJ (1998) Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280(11):975–980PubMedCrossRefGoogle Scholar
  5. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD, PLCO Project Team (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310–1319PubMedCrossRefGoogle Scholar
  6. Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M (2010) Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 16(1):203–211PubMedCrossRefGoogle Scholar
  7. Aron M, Rajeev TP, Gupta NP (2000) Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 85(6):682–685PubMedCrossRefGoogle Scholar
  8. Ash D, Flynn A, Batterman J, de Reijke T, Lavagnini P, Blank L, ESTRA/EAU Urological Brachytherapy Group; EORTC Radiotherapy Group (2000) ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 57(3):315–321PubMedCrossRefGoogle Scholar
  9. Babaian RJ, Donnelly B, Bahn D, Baust JG, Dineen M, Ellis D, Katz A, Pisters L, Rukstalis D, Shinohara K, Thrasher JB (2008) Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol 180(5):1993–2004PubMedCrossRefGoogle Scholar
  10. Beheshti M, Vali R, Langsteger W (2007) [18F]Fluorocholine PET/CT in the assessment of bone metastases in prostate cancer. Eur J Nucl Med Mol Imaging 34(8):1316–1317PubMedCrossRefGoogle Scholar
  11. Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson SO, Bratell S, Spångberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, Norlén BJ, Johansson JE, For the Scandinavian Prostate Cancer Group Study No. 4 (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352(19):1977–1984PubMedCrossRefGoogle Scholar
  12. Bill-Axelson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C, Nordling S, Häggman M, Andersson SO, Bratell S, Spångberg A, Palmgren J, Adami HO, Johansson JE, Scandinavian prostate cancer Group Study Number 4 (2008) Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 100(16):1144–1154PubMedCrossRefGoogle Scholar
  13. Boccon-Gibod L, Hammerer P, Madersbacher S, Mottet N, Prayer-Galetti T, Tunn U (2007) The role of intermittent androgen deprivation in prostate cancer. BJU Int 100(4):738–743PubMedCrossRefGoogle Scholar
  14. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Maréchal JM, Scalliet P, Haustermans K, Piérart M, European Organization for Research and Treatment of Cancer (2005) Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22911). Lancet 366(9485):572–578PubMedCrossRefGoogle Scholar
  15. Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Piérart M, Mauer ME, Collette L, EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360(24):2516–2527PubMedCrossRefGoogle Scholar
  16. Börgermann C, Loertzer H, Hammerer P, Fornara P, Graefen M, Rübben H (2010) Problems, objective, and substance of early detection of prostate cancer. Urologe A 49(2):181–189 [Article in German]PubMedCrossRefGoogle Scholar
  17. Bratt O (2002) Hereditary prostate cancer: clinical aspects. J Urol 168(3):906–913PubMedCrossRefGoogle Scholar
  18. Briganti A, Chun FK, Salonia A, Gallina A, Farina E, Da Pozzo LF, Rigatti P, Montorsi F, Karakiewicz PI (2006) Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU Int 98(4):788–793PubMedCrossRefGoogle Scholar
  19. Briganti A, Passoni N, Ferrari M, Capitanio U, Suardi N, Gallina A, Pozzo LF, Picchio M, Di Girolamo V, Salonia A, Gianolli L, Messa C, Rigatti P, Montorsi F (2010) When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol 57:551–558, Epub 2009 Dec 18PubMedCrossRefGoogle Scholar
  20. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G et al (1999) Eligibility and response ­guidelines for phase II clinical trials in androgen-­independent prostate cancer: recommendations from the prostate-specific antigen working group. J Clin Oncol 17(11):3461–3467PubMedGoogle Scholar
  21. Budäus L, Bolla M, Bossi A, Cozzarini C, Crook J, Widmark A, Wiegel T (2012) Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol Jan;61(1):112–27CrossRefGoogle Scholar
  22. Buonerba C, Palmieri G, Di Lorenzo G (2010) Docetaxel rechallenge in castration-resistant prostate cancer: ­scientific legitimacy of common clinical practice. Eur Urol 58:636–637PubMedCrossRefGoogle Scholar
  23. Byar DP (1973) Proceedings: the Veterans Administration Co-operative Urological Research Group studies of cancer of the prostate. Cancer 32(5):1126–1130PubMedCrossRefGoogle Scholar
  24. Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, Hunt M, Greenstein S, Amols H (2008) Ultrahigh dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 71(2):330–337PubMedCrossRefGoogle Scholar
  25. Carter HB, Kettermann AE, Ferrucci L, Landis P, Trock BJ, Metter EJ (2008) Prostate specific antigen testing among the elderly; when to stop? J Urol 174(2 Suppl 1):600, abstract #1751CrossRefGoogle Scholar
  26. Carvalhal GF, Smith DS, Mager DE, Ramos C, Catalona WJ (1999) Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/ml or less. J Urol 161:835–839PubMedCrossRefGoogle Scholar
  27. Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, Franceschelli A, Martorana G, Manferrari F, Fanti S (2009) Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 50(9):1394–1400PubMedCrossRefGoogle Scholar
  28. Cespedes RD, Pisters LL, von Eschenbach AC, McGuire EJ (1997) Long-term follow-up of incontinence and obstruction after salvage cryosurgical ablation of the prostate: results in 143 patients. J Urol 157(1):237–240PubMedCrossRefGoogle Scholar
  29. Cher ML, Bianco FJ Jr, Lam JS, Davis LP, Grignon DJ, Sakr WA, Banerjee M, Pontes JE, Wood DP Jr (1998) Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 160(4):1387–1391PubMedCrossRefGoogle Scholar
  30. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM, Warner J (1994) Results of conservative management of clinically localized prostate cancer. N Engl J Med 330(4):242–248PubMedCrossRefGoogle Scholar
  31. Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T, Borsatti E, Drigo A, Trovò MG (2006) [18F]Fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 33(12):1387–1398PubMedCrossRefGoogle Scholar
  32. Cirillo S, Petracchini M, Scotti L, Gallo T, Macera A, Bona MC, Ortega C, Gabriele P, Regge D (2009) Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced ­imaging. Eur Radiol 19(3):761–769PubMedCrossRefGoogle Scholar
  33. Cruz Guerra NA (2009) Outcomes from the use of ­maximal androgen blockade in prostate cancer at health area with reference hospital type 2 (1st part). Quality of life: application of EORTC QLQ-C30 instrument. Arch Esp Urol 62(6):431–457PubMedCrossRefGoogle Scholar
  34. D’Amico A, Renshaw AA, Loffredo M, Kantoff PW (2008) Androgen suppression and radiation vs radiation alone for prostate cancer; a randomized controlled trial. JAMA 299(3):289–295PubMedCrossRefGoogle Scholar
  35. D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW (2009) Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death. Int J Radiat Oncol Biol Phys 75(1):10–15PubMedCrossRefGoogle Scholar
  36. Da Pozzo LF, Cozzarini C, Briganti A, Suardi N, Salonia A, Bertini R, Gallina A, Bianchi M, Fantini GV, Bolognesi A, Fazio F, Montorsi F, Rigatti P (2009) Long-term follow- up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol 55(5):1003–1011PubMedCrossRefGoogle Scholar
  37. da Silva FE Calais, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, Kirkali Z, da Silva FM Calais, Robertson C (2009) Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European uroncological group. Eur Urol 55(6):1269–1277CrossRefGoogle Scholar
  38. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, TROPIC Investigators (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant ­prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747):1147–1154PubMedCrossRefGoogle Scholar
  39. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, COU-AA-301 Investigators (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995–2005PubMedCrossRefGoogle Scholar
  40. de Leval J, Boca P, Yousef E, Nicolas H, Jeukenne M, Seidel L, Bouffioux C, Coppens L, Bonnet P, Andrianne R, Wlatregny D (2002) Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 1(3):163–171PubMedGoogle Scholar
  41. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H, Groskopf J (2008) PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 179(4):1587–1589PubMedCrossRefGoogle Scholar
  42. Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Sternberg CN (2010) Castration- resistant prostate cancer: current and emerging treatment strategies. Drugs 70(8):983–1000PubMedCrossRefGoogle Scholar
  43. Donnelly BJ, Saliken JC, Brasher PM, Ernst SD, Rewcastle JC, Lau H, Robinson J, Trpkov K (2010) A randomized trial of external beam radiotherapy versus ­cryoablation in patients with localized prostate cancer. Cancer 116:323–330PubMedCrossRefGoogle Scholar
  44. Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J (2006) Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 175(5):1605–1612PubMedCrossRefGoogle Scholar
  45. Eisenberg ML, Shinohara K (2008) Partial salvage cryoablation of the prostate for recurrent prostate cancer after radiotherapy failure. Urology 72(6):1315–1318PubMedCrossRefGoogle Scholar
  46. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, ISUP Grading Committee (2005) The 2005 International Society of Urologic Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29:1228–1242PubMedCrossRefGoogle Scholar
  47. Eymard JC, Oudard S, Gravis G, Ferrero JM, Theodore C, Joly F, Priou F, Krakowski I, Zannetti A, Thill L, Beuzeboc P (2010) Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int 106:774–778CrossRefGoogle Scholar
  48. Faris JE, Smith MR (2010) Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Curr Opin Endocrinol Diabetes Obes 17(3):240–246PubMedCrossRefGoogle Scholar
  49. Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe 2008. Eur J Cancer 46:765–781PubMedCrossRefGoogle Scholar
  50. Fizazi K, Sternberg CN, Fitzpatrick JM, Watson RW, Tabesh M (2010) Role of targeted therapy in the treatment of advanced prostate cancer. BJU Int 105(6):748–767PubMedCrossRefGoogle Scholar
  51. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768):813–822PubMedCrossRefGoogle Scholar
  52. Fuchsjager M, Shukla-Dave A, Akin O, Barentsz J, Hricak H (2008) Prostate cancer imaging. Acta Radiol 49:107–120PubMedCrossRefGoogle Scholar
  53. Giovacchini G, Picchio M, Briganti A, Cozzarini C, Scattoni V, Salonia A, Landoni C, Gianolli L, Di Muzio N, Rigatti P, Montorsi F, Messa C (2010) [11C]Choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. J Urol 184(3):938–943PubMedCrossRefGoogle Scholar
  54. Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111(1):58–64PubMedGoogle Scholar
  55. Goldner G, Dimopoulos J, Pötter R (2010) Is the Roach formula predictive for biochemical outcome in prostate cancer patients with minimal residual disease undergoing local radiotherapy after radical prostatectomy? Radiother Oncol 94(3):324–327PubMedCrossRefGoogle Scholar
  56. Gomez P, Manoharan M, Kim SS, Soloway MS (2004) Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? BJU Int 94(3):299–302PubMedCrossRefGoogle Scholar
  57. Grossfeld GD, Li YP, Lubeck DP, Broering JM, Mehta SS, Carroll PR (2002) Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor. J Urol 168(2):530–535PubMedCrossRefGoogle Scholar
  58. Hara R, Jo Y, Fujii T, Kondo N, Yokoyoma T, Miyaji Y, Nagai A (2008) Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy. Urology 71(2):191–195PubMedCrossRefGoogle Scholar
  59. Heidenreich A, von Knobloch R, Hofmann R (2001) Current status of cytotoxic chemotherapy in hormone refractory prostate cancer. Eur Urol 39(2):121–130PubMedCrossRefGoogle Scholar
  60. Heidenreich A, Varga Z, Von Knobloch R (2002) Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 167(4):1681–1686PubMedCrossRefGoogle Scholar
  61. Heidenreich A, Ohlmann C, Ozgür E, Engelmann U (2006) Functional and oncological outcome of salvage prostatectomy of locally recurrent prostate cancer following radiation therapy. Urologe A 45(4):474–481PubMedCrossRefGoogle Scholar
  62. Heidenreich A, Semrau R, Thüer D, Pfister D (2008) Radical salvage prostatectomy: treatment of local recurrence of prostate cancer after radiotherapy. Urologe A 47(11):1441–1446PubMedCrossRefGoogle Scholar
  63. Heidenreich A, Richter S, Thüer D, Pfister D (2010) Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. Eur Urol 57(3):437–443PubMedCrossRefGoogle Scholar
  64. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, European Association of Urology (2011a) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59(1):61–71PubMedCrossRefGoogle Scholar
  65. Heidenreich A, Pfister D, Thüer D, Brehmer B (2011b) Percentage of positive biopsies predicts lymph node involvement in men with low-risk prostate cancer undergoing radical prostatectomy and extended pelvic lymphadenectomy. BJU Int 107:220–225PubMedCrossRefGoogle Scholar
  66. Herkommer K, Kuefer R, Gschwend JE, Hautmann RE, Volkmer BG (2004) Pathological T0 prostate cancer without neoadjuvant therapy: clinical presentation and follow-up. Eur Urol 45(1):36–41PubMedCrossRefGoogle Scholar
  67. Hoivels AM, Heesakkers RAM, Adang EM, Jager GJ, Strum S, Hoogeveen YL, Severens JL, Barentsz JO (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63:387–395CrossRefGoogle Scholar
  68. Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A, Cservenyàk T, Hany TF (2008) Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 35(2):253–263PubMedCrossRefGoogle Scholar
  69. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D, Southwest Oncology Group Trial 9346 (INT-0162) (2006) Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest oncology group trial 9346 (INT- 0162). J Clin Oncol 24(24):3984–3990PubMedCrossRefGoogle Scholar
  70. Ilic D, O’Connor D, Green S, Wilt T (2007) Screening for prostate cancer: a Cochrane systematic review. Cancer Causes Control 18(3):279–285PubMedCrossRefGoogle Scholar
  71. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96PubMedCrossRefGoogle Scholar
  72. Joniau S, Hsu CY, Lerut E, Van Baelen A, Haustermans K, Roskams T, Oyen R, Van Poppel H (2007) A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. Eur Urol 51(2):388–396PubMedCrossRefGoogle Scholar
  73. Jordan WP Jr, Blackard CE, Byar DP (1977) Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. South Med J 70(12):1411–1413PubMedGoogle Scholar
  74. Kaisary AV, Iversen P, Tyrrell CJ, Carroll K, Morris T (2001) Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer? Prost Cancer Prost Dis 4(4):196–203CrossRefGoogle Scholar
  75. Kane CJ, Amling CL, Johnstone PAS, Pak N, Lance RS, Thrasher B, Foley JP, Riffenburgh RH, Moul JW (2003) Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 61(3):607–611PubMedCrossRefGoogle Scholar
  76. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, IMPACT Study Investigators (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411–422PubMedCrossRefGoogle Scholar
  77. Klotz L (2010) Active surveillance for prostate cancer: a review. Curr Urol Rep 11(3):165–171PubMedCrossRefGoogle Scholar
  78. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH (2008) The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 102(11):1531–1538PubMedCrossRefGoogle Scholar
  79. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized ­prostate cancer. J Clin Oncol 28(1):126–131PubMedCrossRefGoogle Scholar
  80. Kobori Y, Kitagawa Y, Mizokami A, Komatsu K, Namiki M (2008) Free-to-total prostate-specific antigen (PSA) ratio contributes to an increased rate of prostate cancer detection in a Japanese population screened using a PSA level of 2.1–10.0 ng/ml as a criterion. Int J Clin Oncol 13(3):229–232PubMedCrossRefGoogle Scholar
  81. Krakowsky Y, Loblaw A, Klotz L (2010) Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics. J Urol 184(1):131–135PubMedCrossRefGoogle Scholar
  82. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD (2006) Neo-adjuvant and adjuvant hormone ­therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 4:CD006019PubMedGoogle Scholar
  83. Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A (2005) Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys 61(2):415–419PubMedCrossRefGoogle Scholar
  84. Loeb S, Catalona WJ (2009) What is the role of digital rectal examination in men undergoing serial screening of serum PSA levels? Nat Clin Pract Urol 6(2):68–69PubMedCrossRefGoogle Scholar
  85. Loeb S, Smith ND, Roehl KA, Catalona WJ (2007) Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology 69(6):1170–1175PubMedCrossRefGoogle Scholar
  86. Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, Chauchereau A, Fizazi K (2010) The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer 46(10):1770–1772PubMedCrossRefGoogle Scholar
  87. Lukka H, Waldron T, Chin J, Mayhew L, Warde P, Winquist E, Rodrigues G, Shayegan B (2011) ­High-intensity focused ultrasound for prostate cancer: a systematic review. Clin Oncol (R Coll Radiol) 23(2):117–127CrossRefGoogle Scholar
  88. Manni A, Bartholomew M, Caplan R, Boucher A, Santen R, Lipton A, Harvey H, Simmonds M, White-Hersey D, Gordon R et al (1988) Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 6(9):1456–1466PubMedGoogle Scholar
  89. Massard C, Fizazi K (2011) Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res 17(12):3876–3883PubMedCrossRefGoogle Scholar
  90. McLeod DG (2003) Hormonal therapy: historical perspective to future directions. Urology 61(2 Suppl 1):3–74, LHRH orchiectomyPubMedCrossRefGoogle Scholar
  91. McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP, Casodex Early Prostate Cancer Trialists’ Group (2006) Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 97(2):247–254PubMedCrossRefGoogle Scholar
  92. Merrimen JL, Jones G, Walker D, Leung CS, Kapusta LR, Srigley JR (2009) Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. J Urol 182(2):485–490PubMedCrossRefGoogle Scholar
  93. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-­positive prostate cancer. N Engl J Med 341(24):1781–1788PubMedCrossRefGoogle Scholar
  94. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di SantAgnese PA, Trump D, Eastern Cooperative Oncology Group Study EST 3886 (2006) Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7(6):472–479PubMedCrossRefGoogle Scholar
  95. Morgan SC, Dearnaley DP (2009) Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence? Expert Rev Anticancer Ther 9(7):939–951PubMedCrossRefGoogle Scholar
  96. Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventós CX, Catalán R, Reventós J (2006) Failure to maintain a suppressed level of serum testosterone during long- acting depot luteinizing hormone releasing hormone agonist therapy in patients with advanced prostate cancer. Urol Int 77(2):135–138PubMedCrossRefGoogle Scholar
  97. Mottet N, Peneau M, Mazeron J, Molinie V, Richaud P (2010) Impact of radiotherapy (RT) combined with androgen deprivation (ADT) versus ADT alone for local control in clinically locally advanced prostate cancer. J Clin Oncol 28:15s (suppl; abstr 4505)Google Scholar
  98. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A (2011) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59(4):572–583PubMedCrossRefGoogle Scholar
  99. Moul JW (2009) Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer. Cancer 115(15):3376–3378PubMedCrossRefGoogle Scholar
  100. Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T et al (2004) Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 171:1141–1147PubMedCrossRefGoogle Scholar
  101. Murat FJ, Poissonnier L, Rabilloud M, Belot A, Bouvier R, Rouviere O, Chapelon JY, Gelet A (2009) Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably ­morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur Urol 55(3):640–647PubMedCrossRefGoogle Scholar
  102. Nair B, Wilt T, MacDonald R, Rutks I (2002) Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev 1:CD003506PubMedGoogle Scholar
  103. O’Brien MF, Cronin AM, Fearn PA, Smith B, Stasi J, Guillonneau B, Scardino PT, Eastham JA, Vickers AJ, Lilja H (2009) Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol 27(22):3591–3597PubMedCrossRefGoogle Scholar
  104. Ohlmann CH, Markert E, Gerharz M, Dienes HP, Stöckle M, Engelmann U, Heidenreich A (2011) Improving the efficacy of targeted trials by multiple-marker analysis in castration-resistant prostate cancer. Urol Oncol 29:664–669, Epub 2009 Nov 26PubMedCrossRefGoogle Scholar
  105. Peeters ST, Heemsbergen WD, Koper PCM, van Putten WLJ, Slot A, Dielwart MFH, Bonfrer JMG, Incrocci L, Lebesque JV (2006) Dose–response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24(13):1990–1996PubMedCrossRefGoogle Scholar
  106. Perachino M, Cavalli V, Bravi F (2010) Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 105(5):648–651PubMedCrossRefGoogle Scholar
  107. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin M, Burch PA, Berry D, Mounpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15):1513–1520PubMedCrossRefGoogle Scholar
  108. Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, Montorsi F, Reske SN, Thalmann GN (2011) The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 59(1):51–60PubMedCrossRefGoogle Scholar
  109. Pierorazio PM, Guzzo TJ, Han M, Bivalacqua TJ, Epstein JI, Schaeffer EM, Schoenberg M, Walsh PC, Partin AW (2010) Long-term survival after radical prostatectomy for men with high gleason sum in pathologic specimen. Urology 76:715–721PubMedCrossRefGoogle Scholar
  110. Pinkawa M, Piroth MD, Holy R, Djukic V, Klotz J, Krenkel B, Eble MJ (2011) Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer. Strahlenther Onkol Aug;187(8):479–84CrossRefGoogle Scholar
  111. Pisters LL, von Eschenbach AC, Scott SM, Swanson DA, Dinney CPM, Pettaway CA, Babaian RJ (1997) The efficacy and complications of salvage cryotherapy of the prostate. J Urol 157(3):921–925PubMedCrossRefGoogle Scholar
  112. Pisters LL, Rewcastle JC, Donnelly BJ, Lugnani FM, Katz AE, Jones JS (2008) Salvage prostate cryoablation: initial results from the cryo on-line data registry. J Urol 180(2):559–563; discussion 563–564PubMedCrossRefGoogle Scholar
  113. Pisters LL, Leibovici D, Blute M, Zincke H, Sebo TJ, Slezak JM, Izawa J, Ward JF, Scott SM, Madsen L, Spiess PE, Leibovich BC (2009) Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J Urol 182(2):517–525PubMedCrossRefGoogle Scholar
  114. Ploussard G, Haese A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Bastien L, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, van Gils MP, Schalken JA, de la Taille A (2010) The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? BJU Int 106:1143–1147PubMedCrossRefGoogle Scholar
  115. Pommier P, Chabaud S, Lagrange JL, Richaud P, Lesaunier F, Le Prise E, Wagner JP, Hay MH, Beckendorf V, Suchaud JP, Pabot du Chatelard JM, Bernier V, Voirin N, Perol D, Carrie C (2007) Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 25(34):5366–5373. Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H (2006) Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176(4 PT 1):1415–1419Google Scholar
  116. Remzi M, Haese A, van Poppel H, de la Taille A, Stenzl A, Hennenlotter J, Marberger M (2010) Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer? BJU Int 106:1138–1142PubMedCrossRefGoogle Scholar
  117. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference. Int J Radiat Biol Phys 65:965–974CrossRefGoogle Scholar
  118. Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Carter HB, Walsh PC (2010) Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 28(17):2810–2816PubMedCrossRefGoogle Scholar
  119. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goad JA, Chen B (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J Natl Cancer Inst 94(19):1458–1468PubMedCrossRefGoogle Scholar
  120. Saylor PJ, Smith MR (2009) Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 181(5):1998–2006PubMedCrossRefGoogle Scholar
  121. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, Prostate Cancer Clinical Trials Working Group (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 26(7):1148–1159PubMedCrossRefGoogle Scholar
  122. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL, Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium (2010) Antitumour activity of MDV3100 in castration-­resistant prostate cancer: a phase 1–2 study. Lancet 375(9724):1437–1446, Epub 2010 Apr 14PubMedCrossRefGoogle Scholar
  123. Schiavina R, Scattoni V, Castellucci P, Picchio M, Corti B, Briganti A, Franceschelli A, Sanguedolce F, Bertaccini A, Farsad M, Giovacchini G, Fanti S, Grigioni WF, Fazio F, Montorsi F, Rigatti P, Martorana G (2008) (11)C-choline positron emission tomography/computerized tomography for preoperative lymph node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 54(2):392–401PubMedCrossRefGoogle Scholar
  124. Schmitt B, Wilt TJ, Schellhammer PF, De Masi V, Sartor O, Crawford ED, Bennett CL (2001) Combined ­androgen blockade with non-steroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 57(4):727–732PubMedCrossRefGoogle Scholar
  125. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A, ERSPC Investigators (2009a) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320–1328PubMedCrossRefGoogle Scholar
  126. Schröder FH, Kurth KH, Fossa SD, Hoekstra W, Karthaus PP, De Prijck L, Collette L (2009b) Early versus delayed endocrine treatment of T2-T3 pN1–3 M0 prostate cancer without local treatment of the primary tumour: final results of European organisation for the research and treatment of cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). Eur Urol 55(1):14–22PubMedCrossRefGoogle Scholar
  127. Schulman CC, Irani J, Morote J, Schalken JA, Montorsi F, Chlosta PL, Heidenreich A (2010) Testosterone measurement in patients with prostate cancer. Eur Urol 58:65–74PubMedCrossRefGoogle Scholar
  128. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ (2000) Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 132(7):566–577PubMedGoogle Scholar
  129. Serpa Neto A, Tobias-Machado M, Esteves MA, Senra MD, Wroclawski ML, Fonseca FL, Dos Reis RB, Pompeo AC, Del Giglio A (2010) A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma. BMC Urol 10:9PubMedCrossRefGoogle Scholar
  130. Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD (2009) A systematic review and meta- analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 35(1):9–17PubMedCrossRefGoogle Scholar
  131. Slovin SF, Wilton AS, Heller G, Scher HI (2005) Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clin Cancer Res 11(24 Pt 1):8669–8673PubMedCrossRefGoogle Scholar
  132. Sobin LH, Gospodariwicz M, Wittekind C (eds) (2009) TNM classification of malignant tumors. UICC international union against cancer, 7th edn. Wiley-Blackwell, New York, pp 243–248Google Scholar
  133. Stephenson AJ, Eastham JA (2005) Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol 23(32):8198–8203PubMedCrossRefGoogle Scholar
  134. Stephenson AJ, Scardino PT, Bianco FJ, DiBlasio CJ, Fearn PA, Eastham JA (2004) Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol 172(6 Pt 1):2239–2243PubMedCrossRefGoogle Scholar
  135. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ, Lilja H, Scardino PT (2006) Defining ­biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 24(24):3973–3978PubMedCrossRefGoogle Scholar
  136. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn CG, Catton CN, DeWeese TL, Liauw SL, Valicenti RK, Kuban DA, Pollack A (2007) Predicting outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25(15):2035–2041PubMedCrossRefGoogle Scholar
  137. Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, Eymard JC, Falcon S, Calabrò F, James N, Bodrogi I, Harper P, Wirth M, Berry W, Petrone ME, McKearn TJ, Noursalehi M, George M, Rozencweig M (2009) Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 27(32):5431–5438PubMedCrossRefGoogle Scholar
  138. Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, Loidl W, Isorna S, Sundaram SK, Debois M, Collette L (2006) Immediate or deferred androgen deprivation for patients with prostate cancer not ­suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) trial 30891. J Clin Oncol 24(12):1868–1876PubMedCrossRefGoogle Scholar
  139. Studer UE, Collette L, Whelan P, Albrecht W, Casselman J, de Reijke T, Knönagel H, Loidl W, Isorna S, Sundaram SK, Debois M, EORTC Genitourinary Group (2008) Using PSA to guide timing of androgen deprivation in patients with T0–4N0–2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 53(5):941–949PubMedCrossRefGoogle Scholar
  140. Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM, Crawford ED (2007) Predominant treatrment failure in postprostatectomy patients is local: analysis of ­patterns of treatment failure in SWOG 8794. J Clin Oncol 25(16):222–229CrossRefGoogle Scholar
  141. Swanson GP, Thompson IM, Tangen C, Paradelo J, Cany-Hagino E, Crawford ED, Miller G, Lucia MS, Forman J, Chin J (2008) Update of SWOG 8794: adjuvant radiotherapy for pT3 prostate cancer improves metastasis free survival. Int J Radiat Oncol Biol Phys 72:S31CrossRefGoogle Scholar
  142. Taira AV, Merrick GS, Butler WM, Galbreath RW, Lief J, Adamovich E, Wallner KE (2011) Long- term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 79:1336–1342, Epub 2010 Jun 3PubMedCrossRefGoogle Scholar
  143. Takenaka A, Hara R, Ishimura T et al (2008) A prospective randomized comparison of diagnostic efficiency between transperineal and transrectal 12-core prostate biopsy. Prostate Cancer Prostatic Dis 11:134–138PubMedCrossRefGoogle Scholar
  144. Talcott JA, Rossi C, Shipley WU, Clark JA, Slater JD, Niemierko A, Zietman AL (2010) Patient- reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA 303(11):1046–1053PubMedCrossRefGoogle Scholar
  145. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Ourdard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger M, TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512PubMedCrossRefGoogle Scholar
  146. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per millilitre. N Engl J Med 350(22):2239–2246PubMedCrossRefGoogle Scholar
  147. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long- term followup of a randomized clinical trial. J Urol 181(3):956–962PubMedCrossRefGoogle Scholar
  148. Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Crawford ED, Moul J, Jensen JK, Kold Olesen T, Persson BE (2009) Additional analysis of the secondary End point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol 57:836–842PubMedCrossRefGoogle Scholar
  149. Trock BJ, Han M, Freedland SJ et al (2008) Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299:2760–2769PubMedCrossRefGoogle Scholar
  150. Trpkov K, Gao Y, Hay R, Yimaz A (2006) No residual cancer on radical prostatectomy after positive 10-core biopsy: incidence, biopsy findings, and DNA specimen identity analysis. Arch Pathol Lab Med 130(6):811–816PubMedGoogle Scholar
  151. Tyrrell CJ, Denis L, Newling DWW, Soloway M, Channer K, Cockshott ID (1998a) Casodex 10–200 mg daily, used as monotherapy for patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose- ranging studies. Casodex study group. Eur Urol 33(1):39–53PubMedCrossRefGoogle Scholar
  152. Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, Chamberlain M, Webster A, Blackledge G (1998b) A randomized comparison of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33(5):447–456PubMedCrossRefGoogle Scholar
  153. Uchida T, Shoji S, Nakano M, Hongo S, Nitta M, Usui Y, Nagata Y (2011) High-intensity focused ultrasound as salvage therapy for patients with recurrent prostate cancer after external beam radiation, brachytherapy or proton therapy. BJU Int 107(3):378–382PubMedCrossRefGoogle Scholar
  154. Van der Kwast TH, Lopes C, Santonja C, Pihl CG, Neetens I, Martikainen P, Di Lollo S, Bubendorf L, Hoedemaeker RF, Members of the pathology committee of the European Randomised Study of Screening for Prostate Cancer (2003) Guidelines for processing and reporting of prostatic needle biopsies. J Clin Pathol 56(5):336–340PubMedCrossRefGoogle Scholar
  155. van Leeuwen PJ, Connolly D, Gavin A, Roobol MJ, Black A, Bangma CH, Schröder FH (2010) Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. Eur J Cancer 46(2):377–383PubMedCrossRefGoogle Scholar
  156. Van Poppel H, Joniau S (2008) An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. Eur Urol 53(2):253–259PubMedCrossRefGoogle Scholar
  157. Vickers AJ, Savage C, O’Brien MF, Lilja H (2009) Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 27(3):398–403PubMedCrossRefGoogle Scholar
  158. Wang L, Hricak H, Kattan MW, Chen HN, Kuroiwa K, Eisemberg HF (2007) Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MRI to the kattan nomogram. Radiology 242(1):182–188PubMedCrossRefGoogle Scholar
  159. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H (2005) Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-­specific antigen testing: 15-year outcome. BJU Int 95(6):751–756PubMedCrossRefGoogle Scholar
  160. Warde R, Mason MD, Sydes MR, Gospodarowicz MK, Swanson GP, Kirkbride P, Kostashuk E, Hetherington J, Ding K, Parulekar W (2010) NCIC CTG PR.3/ MRC PRO7/ SWOG JPR3 investigators. Intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94–0110; NCT00002633). J Clin Oncol 28:18s (suppl; abstr CRA4504)Google Scholar
  161. Warmuth M et al (2010) Systematic review of the efficacy and safety of high-intensity focussed ultrasound for the primary and salvage treatment of prostate cancer. Eur Urol. doi: 10.1016/j.eururo.2010.09.009
  162. Westphalen AC, Coakley FV, Roach M 3rd, McCulloch CE, Kurhanewicz J (2010) Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection. Radiology 256(2):485–492PubMedCrossRefGoogle Scholar
  163. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Fosså SD, Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3 (2009) Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 373(9660):301–308PubMedCrossRefGoogle Scholar
  164. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96–02/AUO AP 09/95. J Clin Oncol 27(18):2924–2930PubMedCrossRefGoogle Scholar
  165. Wong YN, Freedland S, Egleston B, Hudes G, Schwartz JS, Armstrong K (2009) Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol 27(1):100–105PubMedCrossRefGoogle Scholar
  166. Yossepowitch O, Eggener SE, Bianco FJ Jr, Carver BS, Serio A, Scardino PT, Eastham JA (2007) Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 178(2):493–499; discussion 499PubMedCrossRefGoogle Scholar
  167. Yu EY, Gulati R, Telesca D, Jiang P, Tam S, Russell KJ, Nelson PS, Etzioni RD, Higano CS (2010) Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol 28(16):2668–2673PubMedCrossRefGoogle Scholar

Suggested Reading

  1. (1997) Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: ­initial results of the Medical Research Council Trial. Br J Urol 79(2):235–246Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Department of UrologyRWTH University AachenAachenGermany

Personalised recommendations